Press Release
December 18, 2020

Arvinas, Inc. Closes $400 Million Public Offering Of Common Stock

The Life Sciences IPOs + Capital Markets team advised Goldman Sachs & Co. LLC and the other underwriters of Arvinas, Inc.’s (Nasdaq: ARVN) public offering of 5,714,286 shares of its common stock at a price of $70 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 857,142 shares of common stock at the public offering price, less the underwriting discounts and commissions.

Arvinas is a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine.

The Goodwin team was led by Rob Puopolo, and Peter Rodas, and included Steven Tjoe and Olivia Uitto.

For more details, read the press release and articles from S&P Global and Seeking Alpha.